COURT-RULING filed Jul 26, 2026 at 20:00 ET
AstraZeneca's challenge to Maine's 340B contract pharmacy law (Chapter 103) was dismissed by the District of Maine. The court granted the state's motion to dismiss, finding AstraZeneca failed to state plausible claims for federal preemption, Contracts Clause violation, or Takings Clause violation. This is a loss for AstraZeneca in its effort to block state restrictions on manufacturer limits to 340B contract pharmacies, but the ruling is consistent with multiple other district and circuit court decisions on similar state laws, and the financial impact alleged by AstraZeneca ($3.6M/year in savings from a single-pharmacy limit) is trivial relative to its $265.7B market cap, making this a low-impact, confirmatory legal development with no immediate operational disruption.